Glucocorticoids

Glucocorticoids has been studied in 165 papers since 1976: 88 observational studies in people, 12 in animals, 6 in cells, 55 reviews; 62 in the past year. The newest story, Nov 21, 2026: “Steroid-response pattern linked to higher blood-clot risk”.

Exposure

165 papers study it123 findingsUpdated

MeSH

Research on it is growing 6% faster than aging research as a whole: 40 papers in the latest year counted

14 new papers in 30 daysSee all 164 papers on glucocorticoids

At a glance

Independent labs found the same change in cells and people. 59 independent labs in 24 countries.

“TNX levels remained unchanged following acute glucocorticoid administration.”
Tenascin X and Tenascin C Serum Levels in Relation to Age and Cardiometabolic Risk ParametersInternational journal of molecular sciences2026doi:10.3390/ijms27209180

4 of its findings point the other way.

Cells and humans: replicated by independent labs. Mice: a single group. Worms or flies: nothing yet.
  • 59 independent labs in 24 countries
  • 4 findings against
  • Funders: National Cancer Institute and others
  • 9 of 91 findings with company ties
  • Humans88
  • Animals12
  • Cells6
  • In silico3

What did studies of glucocorticoids find?

47

Studies of glucocorticoids measured 47 outcomes; the most studied are cellular senescence (9 studies), autophagy (2) and osteoporosis (2).

Cellular senescence

upin reviews4upin human cells2downin human cells1upin mice1+1

9 studies
  1. Glucocorticoids increase cellular senescence (chronic exposure).

    Reviewchronic exposure

  2. Glucocorticoids induce cellular senescence (chronic glucocorticoid excess).

    Reviewchronic glucocorticoid excess

  3. Glucocorticoids induce cellular senescence in mouse cells (high-dose GC stimulation for 48 h) (6.2-fold).

    Cellshigh-dose GC stimulation for 48 h

  4. Glucocorticoids increase cellular senescence following glucocorticoid therapy.

    Reviewfollowing glucocorticoid therapy

  5. Glucocorticoids induce cellular senescence in mice (upon glucocorticoid treatment).

    Animalsupon glucocorticoid treatmentbone marrow

  6. Glucocorticoids induce cellular senescence.

    Review

  7. Glucocorticoids increase cellular senescence in human cells (chronic pre-exposure during primitive hematopoiesis).

    Cellschronic pre-exposure during primitive hematopoiesis

  8. Glucocorticoids increase cellular senescence in human cells (continuous pre-exposure during primitive haematopoiesis).

    Cellscontinuous pre-exposure during primitive haematopoiesis

  9. Glucocorticoids decrease cellular senescence in human cells (B-RAF-V600E-induced senescence).

    CellsB-RAF-V600E-induced senescence

More on Cellular senescence

Autophagy

downin mouse cells1downin reviews1

2 studies
  1. Glucocorticoids inhibit autophagy (chronic exposure).

    Reviewchronic exposure

  2. Glucocorticoids inhibit autophagy in mouse cells (high-dose GC stimulation for 48 h).

    Cellshigh-dose GC stimulation for 48 h

More on Autophagy

Osteoporosis

upin humans1no changein humans1

2 studies
  1. Glucocorticoids were not clearly linked with osteoporosis in humans (multiple sclerosis).

    Humansmultiple sclerosisn = 159

  2. Glucocorticoids induce osteoporosis in patients with rheumatic diseases.

    Reviewin patients with rheumatic diseases

More on Osteoporosis

Breast cancer

no changein humans1downin reviews1HR 0.94

2 studies
  1. Glucocorticoids were not clearly linked with breast cancer in humans (Postmenopausal women; compared with non-exposure) (HR 0.94 (0.85–1.05)).

    HumansPostmenopausal women; compared with non-exposuresystemicMedian follow-up of 9 yearsfemalesn = 62,512

  2. Glucocorticoids decrease breast cancer in hormone receptor-positive breast cancer.

    Reviewin hormone receptor-positive breast cancer

More on Breast cancer

cGAS-positive micronuclei

upin human cells2

2 studies
  1. Glucocorticoids increase cGAS-positive micronuclei in human cells (chronic pre-exposure during primitive hematopoiesis).

    Cellschronic pre-exposure during primitive hematopoiesis

  2. Glucocorticoids increase cGAS-positive micronuclei in human cells (continuous pre-exposure during primitive haematopoiesis).

    Cellscontinuous pre-exposure during primitive haematopoiesis

More on cGAS-positive micronuclei

Type I interferon signaling

upin human cells2

2 studies
  1. Glucocorticoids increase type I interferon signaling in human cells (chronic pre-exposure during primitive hematopoiesis).

    Cellschronic pre-exposure during primitive hematopoiesis

  2. Glucocorticoids increase type I interferon signaling in human cells (continuous pre-exposure during primitive haematopoiesis).

    Cellscontinuous pre-exposure during primitive haematopoiesis

More on Type I interferon signaling

ACBP/DBI expression and secretion

upin reviews1

1 study
  1. Glucocorticoids increase ACBP/DBI expression and secretion.

    Review

More on ACBP/DBI expression and secretion

ocular inflammation

downin humans1

1 study
  1. Glucocorticoids are linked with lower ocular inflammation in humans (IDH2-mutant clonal hematopoiesis-associated uveitis).

    HumansIDH2-mutant clonal hematopoiesis-associated uveitistopical and intravitreal treatmenteyemalesn = 2

Serum tenascin X

no changein humans1

1 study
  1. Glucocorticoids showed no clear effect on serum tenascin X in humans.

    Human trialserumacute

More on Serum tenascin X

Pituitary enlargement and stalk thickening

downin humans1

1 study
  1. Glucocorticoids are linked with lower pituitary enlargement and stalk thickening in humans (suspected hypothalamic-pituitary sarcoidosis).

    Humanssuspected hypothalamic-pituitary sarcoidosispituitary glandmales

All 47

What is glucocorticoids linked with?

47

Studies link glucocorticoids with 47 measures, most often bone fracture (5 studies), osteoporosis (4) and frailty (4).

Bone fracture

upin humans5

5 studies
  1. Glucocorticoids are linked with a higher risk of bone fracture in patients with MG.

    Humansin patients with MG

  2. Glucocorticoids predict bone fracture in humans (< 2 years after inclusion).

    Humans< 2 years after inclusionfemales

  3. Glucocorticoids are linked with a higher risk of bone fracture in humans.

    Humans5 yearsfemalesn = 854

  4. Glucocorticoids raise the risk of bone fracture in atopic dermatitis.

    Reviewin atopic dermatitissystemic

  5. Glucocorticoids raise the risk of bone fracture in humans (glucocorticoid users compared with non-users).

    Reviewglucocorticoid users compared with non-users

More on Bone fracture

Osteoporosis

upin humans3upin silico1OR 1.63

4 studies
  1. Glucocorticoids are linked with a higher risk of osteoporosis in humans (virologically suppressed PLWH).

    Humansvirologically suppressed PLWHmales

  2. Glucocorticoids raise the risk of osteoporosis in patients with systemic lupus erythematosus (OR = 1.63).

    Reviewin patients with systemic lupus erythematosuslong-term

  3. Glucocorticoids raise the risk of osteoporosis in silico.

    In silicon = 1,958

  4. Glucocorticoids raise the risk of osteoporosis in humans.

    Review

More on Osteoporosis

Frailty

upin humans4OR 2.9–6.21

4 studies
  1. Glucocorticoids are associated with frailty in patients with rheumatoid arthritis (OR 2.90).

    Humansin patients with rheumatoid arthritis

  2. Glucocorticoids are linked with a higher risk of frailty in patients with rheumatoid arthritis (OR 6.21).

    Humansin patients with rheumatoid arthritis1 yearn = 104

  3. Glucocorticoids are associated with frailty in patients with Behçet's syndrome (50%, p=0.030).

    Humansin patients with Behçet's syndromen = 44

  4. Glucocorticoids are associated with frailty in humans (systemic sclerosis) (p=0.011).

    Humanssystemic sclerosisn = 94

Sarcopenia

upin humans1downin humans1upin reviews1OR 0.72–5.25

3 studies
  1. Glucocorticoids are linked with a higher risk of sarcopenia in humans (rheumatoid arthritis) (OR 5.25, 95% CI 2.14 to 24.18).

    Humansrheumatoid arthritisn = 289

  2. Glucocorticoids are linked with a lower risk of sarcopenia in humans (adult childhood cancer survivors) (OR 0.72 (95% CI 0.56 to 0.93)).

    Humansadult childhood cancer survivorsn = 1,762

  3. Glucocorticoids are associated with sarcopenia (chronic elevation).

    Reviewchronic elevation

More on Sarcopenia

Fracture risk

upin humans2

2 studies
  1. Glucocorticoids raise the risk of fracture risk in humans following GC initiation.

    Reviewfollowing GC initiation

  2. Glucocorticoids raise the risk of fracture risk in humans.

    Review

Hip fracture

upin humans2HR 1.7–5.3

2 studies
  1. Glucocorticoids are linked with a higher risk of hip fracture in humans (HR 1.7-5.3).

    Humans35 yrfemalesn = 11,169

  2. Glucocorticoids are linked with a higher risk of hip fracture in humans (SIR 1.62 (95% CI 1.53-1.71)).

    Humansmales

More on Hip fracture

Major osteoporotic fractures

upin humans2OR 1.74

2 studies
  1. Glucocorticoids are associated with major osteoporotic fractures in humans (Postmenopausal women with rheumatoid arthritis).

    HumansPostmenopausal women with rheumatoid arthritisCumulative dosePrevious five yearsfemalesn = 330

  2. Glucocorticoids are associated with major osteoporotic fractures in humans (Current use in patients with sarcoidosis) (Adjusted OR 1.74; 95% CI 1.17–2.58).

    HumansCurrent use in patients with sarcoidosisn = 124

More on Major osteoporotic fractures

Mortality

upin humans1upin Papio1HR 2.037

2 studies
  1. Glucocorticoids are associated with mortality in humans (osteoporosis and vertebral fractures) (HR 2.037, 95% CI 1.187-3.498; p = 0.010).

    Humansosteoporosis and vertebral fracturesn = 210

  2. Glucocorticoids raise the risk of mortality in Papio (wild population; high current or high lifelong cumulative fecal glucocorticoids) (5.4 years of life lost (GCs in top 90% vs bottom 10% for age)).

    Animalswild population; high current or high lifelong cumulative fecal glucocorticoids1634 female yearsfemalesn = 242

Bone mineral density

downin humans1

1 study
  1. Glucocorticoids are associated with bone mineral density in humans (patients with rheumatic diseases receiving glucocorticoid therapy).

    Humanspatients with rheumatic diseases receiving glucocorticoid therapy93.3% femalesn = 223

More on Bone mineral density

Major incident fracture

downin humans1HR 0.48

1 study
  1. Glucocorticoids are associated with major incident fracture in humans (Non-use of oral glucocorticoids) (HR 0.48, 95% CI 0.31–0.75).

    HumansNon-use of oral glucocorticoidsMedian follow-up 16.3 years

More on Major incident fracture

All 47

Funding

7 grants since 2021

National Institute on Aging$2.1MSwiss National Science FoundationCHF 917KNational Institute of Diabetes and Digestive and Kidney Diseases$249K

Latest

Dec 2025: 5Jan 2026: 8Feb 2026: 3Mar 2026: 5Apr 2026: 4May 2026: 4Jun 2026: 4Jul 2026: 2Aug 2026: 5Sep 2026: 5Oct 2026: 8Nov 2026: 861 papers in 12 months
Authorea Preprints

Steroid-response pattern linked to higher blood-clot risk

The pattern appeared in 28.7% of glucocorticoid users and involved reduced clot breakdown and injury to the protective coating inside blood vessels.The pattern appeared in 28.7% of glucocorticoid users and involved reduced clot breakdown and injury to the protective coating inside blood vessels.

Preprint: cohort study of 46,782 peopleBiomarkers

See all 164 papers on glucocorticoids